The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Malignant Transformation and Antineoplastic Actions of Nonsteroidal Antiinflammatory Drugs (Nsaids) on Cyclooxygenase-Null Embryo Fibroblasts
Open accessAbstract
In this study, we use primary embryonic fibroblasts derived from cyclooxygenase-deficient transgenic embryos to further investigate the role of the two cyclooxygenases, cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2), in the process of neoplastic transformation. Cells with either, neither, or both of the cyclooxygenases were transformed by Ha-ras and/or SV40. Our results show that when a cyclooxygenase enzyme is present, the transformed cells have marked increases in COX-2 and/or COX-1 expression. Nevertheless, each type of cell, deficient in either or both cyclooxygenases, can be readily transformed at almost equal efficiency. Different nonsteroidal antiinflammatory drugs (NSAIDs) were used to examine their possible antineoplastic effects on the transformed cells, which have various levels of expression of COX-1 or COX-2. Our results show that NSAIDs suppress the colony formation in soft agar in a dosage-dependent manner in the absence of the cyclooxygenase(s). Thymidine incorporation and apoptosis analyses further demonstrate that the NSAIDs are effective in the cyclooxygenase-null cells. Our findings with cyclooxygenase knockout cells confirm recent reports that some of the antiproliferative and antineoplastic effects of NSAIDs are independent of the inhibition of either COX-1 or COX-2. They also show that transformation is independent of the status of cyclooxygenase expression, suggesting that the involvement of the cyclooxygenases in tumorigenesis may occur at later steps.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804 · cited 1×
“The expression of a mutant ras gene usually does not by itself lead to a transformed phenotype in primary cultured cells; additional mutations in other protooncogenes such as c-myc, or inactivation of tumor suppressor genes such as p53, are required to achieve a full malignant transformation (21).”
BackgroundUp-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., & Dubois, R. N. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90246-1 · Cited by 2,514
Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., & Taketo, M. M. (1996) · Cell · doi:10.1016/s0092-8674(00)81988-1 · Cited by 2,366
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81433-6 · Cited by 2,272
Tsujii, M., & DuBois, R. N. (1995) · Cell · doi:10.1016/0092-8674(95)90127-2 · Cited by 2,267
Kujubu, D. A., Fletcher, B. S., Varnum, B. C., Lim, R. W., & Herschman, H. R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98774-0 · Cited by 1,789
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
Tsujii, M., Kawano, S., & DuBois, R. N. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3336 · Cited by 1,398
Herschman, H. R. (1996) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(95)00194-8 · Cited by 1,197
Langenbach, R., Morham, S. G., Tiano, H. F., Loftin, C. D., Ghanayem, B. I., Chulada, P. C., Mahler, J. F., Lee, C. A., Goulding, E. H., Kluckman, K. D., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90126-4 · Cited by 1,123
Self-citation
Cited by
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
Simmons, D. L., Botting, R. M., & Hla, T. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.3 · Cited by 1,693
Surh, Y.-J., Chun, K.-S., Cha, H.-H., Han, S. S., Keum, Y.-S., Park, K.-K., & Lee, S. S. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00183-x · Cited by 1,620
Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets
Wang, B., Wu, L., Chen, J., Dong, L., Chen, C., Wen, Z., Hu, J., Fleming, I., & Wang, D. W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00443-w · Cited by 1,414
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388
PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs
He, T.-C., Chan, T. A., Vogelstein, B., & Kinzler, K. W. (1999) · Cell · doi:10.1016/s0092-8674(00)81664-5 · Cited by 1,085
Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2
Gupta, R. A., & DuBois, R. N. (2001) · Nature Reviews Cancer · doi:10.1038/35094017 · Cited by 1,066
Murakami, M., Naraba, H., Tanioka, T., Semmyo, N., Nakatani, Y., Kojima, F., Ikeda, T., Fueki, M., Ueno, A., Oh-ishi, S., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003505200 · Cited by 964
Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice
Liu, C. H., Chang, S.-H., Narko, K., Trifan, O. C., Wu, M.-T., Smith, E., Haudenschild, C., Lane, T. F., & Hla, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010787200 · Cited by 807
Cyclooxygenase‐independent actions of cyclooxygenase inhibitors
Tegeder, I., Pfeilschifter, J., & Geisslinger, G. (2001) · The FASEB Journal · doi:10.1096/fj.01-0390rev · Cited by 747
Mining the Wnt pathway for cancer therapeutics
Barker, N., & Clevers, H. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2154 · Cited by 743
Cyclooxygenase 2: a molecular target for cancer prevention and treatment
Subbaramaiah, K., & Dannenberg, A. J. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)00043-3 · Cited by 649
Zhang, X., Schwarz, E. M., Young, D. A., Puzas, J. E., Rosier, R. N., & O’Keefe, R. J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215681 · Cited by 577
Self-citationCyclo-oxygenase 2: a pharmacological target for the prevention of cancer
Dannenberg, A. J., Altorki, N. K., Boyle, J. O., Dang, C., Howe, L. R., Weksler, B. B., & Subbaramaiah, K. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00488-0 · Cited by 508
Grösch, S., Tegeder, I., Niederberger, E., Bräutigam, L., & Geisslinger, G. (2001) · The FASEB Journal · doi:10.1096/fj.01-0299fje · Cited by 501
Many actions of cyclooxygenase‐2 in cellular dynamics and in cancer
Cao, Y., & Prescott, S. M. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10068 · Cited by 464
Distinct functions of COX-1 and COX-2
Morita, I. (2002) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(02)00029-1 · Cited by 462
Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention
Dannenberg, A. J., Lippman, S. M., Mann, J. R., Subbaramaiah, K., & DuBois, R. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.112 · Cited by 404
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
Howe, L. R., Subbaramaiah, K., Brown, A. M., & Dannenberg, A. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080097 · Cited by 322
Cyclooxygenase-2 expression in human pancreatic adenocarcinomas
Yip-Schneider, M. T. (2000) · Carcinogenesis · doi:10.1093/carcin/21.2.139 · Cited by 292
Cyclooxygenase 2 is a key enzyme for inflammatory cytokine‐induced angiogenesis
Kuwano, T., Nakao, S., Yamamoto, H., Tsuneyoshi, M., Yamamoto, T., Kuwano, M., & Ono, M. (2004) · The FASEB Journal · doi:10.1096/fj.03-0473com · Cited by 279
WNT signaling in glioblastoma and therapeutic opportunities
Lee, Y., Lee, J.-K., Ahn, S. H., Lee, J., & Nam, D.-H. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2015.140 · Cited by 273
The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells
Smith, M.-L., Hawcroft, G., & Hull, M. A. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00333-0 · Cited by 252
Metadata
- Authors
- Zhang, X., Morham, S. G., Langenbach, R., & Young, D. A.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1999-08-16
- Volume
- 190
- Issue
- 4
- Pages
- 451-460
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2117858791
- Cited by
- 273
- References
- 38
- FWCI
- 15.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.